These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32708735)

  • 1. DNA Methylation Dysfunction in Chronic Kidney Disease.
    Ingrosso D; Perna AF
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology.
    Morgado-Pascual JL; Marchant V; Rodrigues-Diez R; Dolade N; Suarez-Alvarez B; Kerr B; Valdivielso JM; Ruiz-Ortega M; Rayego-Mateos S
    Mediators Inflamm; 2018; 2018():2931049. PubMed ID: 30647531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery.
    Cappuccilli M; Bergamini C; Giacomelli FA; Cianciolo G; Donati G; Conte D; Natali T; La Manna G; Capelli I
    Nutrients; 2020 Apr; 12(5):. PubMed ID: 32349312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics of kidney disease.
    Wanner N; Bechtel-Walz W
    Cell Tissue Res; 2017 Jul; 369(1):75-92. PubMed ID: 28286899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiology of chronic kidney disease].
    Noël D; Landais P
    Rev Prat; 2012 Jan; 62(1):38-42. PubMed ID: 22335065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular disease.
    Zawada AM; Rogacev KS; Heine GH
    Nephrol Dial Transplant; 2013 Jul; 28(7):1663-71. PubMed ID: 23512108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics of progression of chronic kidney disease: fact or fantasy?
    Wing MR; Ramezani A; Gill HS; Devaney JM; Raj DS
    Semin Nephrol; 2013 Jul; 33(4):363-74. PubMed ID: 24011578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current epigenetic aspects the clinical kidney researcher should embrace.
    Witasp A; Van Craenenbroeck AH; Shiels PG; Ekström TJ; Stenvinkel P; Nordfors L
    Clin Sci (Lond); 2017 Jul; 131(14):1649-1667. PubMed ID: 28667065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Kidney Injury: Tubular Markers and Risk for Chronic Kidney Disease and End-Stage Kidney Failure.
    Tan HL; Yap JQ; Qian Q
    Blood Purif; 2016; 41(1-3):144-50. PubMed ID: 26764483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.
    Kato M; Natarajan R
    Nat Rev Nephrol; 2019 Jun; 15(6):327-345. PubMed ID: 30894700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrotic Changes Mediating Acute Kidney Injury to Chronic Kidney Disease Transition.
    Ó hAinmhire E; Humphreys BD
    Nephron; 2017; 137(4):264-267. PubMed ID: 28595180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factors and epigenetic modulation: its therapeutic implication in chronic kidney disease.
    Hayashi K; Itoh H
    Arch Immunol Ther Exp (Warsz); 2015 Jun; 63(3):193-6. PubMed ID: 25503375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study.
    Khan YH; Sarriff A; Adnan AS; Khan AH; Mallhi TH; Jummaat F
    Nephrology (Carlton); 2017 Jan; 22(1):25-34. PubMed ID: 26718476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease.
    Larkin BP; Glastras SJ; Chen H; Pollock CA; Saad S
    FASEB J; 2018 Oct; 32(10):5215-5226. PubMed ID: 29688808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fukuoka Kidney disease Registry (FKR) Study: design and methods.
    Tanaka S; Ninomiya T; Fujisaki K; Yoshida H; Nagata M; Masutani K; Tokumoto M; Mitsuiki K; Hirakata H; Fujimi S; Kiyohara Y; Kitazono T; Tsuruya K;
    Clin Exp Nephrol; 2017 Jun; 21(3):465-473. PubMed ID: 27339444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based cohort study defines prognoses in severe chronic kidney disease.
    Tonelli M; Wiebe N; James MT; Klarenbach SW; Manns BJ; Ravani P; Strippoli GFM; Hemmelgarn BR;
    Kidney Int; 2018 May; 93(5):1217-1226. PubMed ID: 29525394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).
    Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M
    Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease.
    Karsli Ceppioğlu S; Yurdun T; Canbakan M
    Ren Fail; 2011; 33(9):866-74. PubMed ID: 21859400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular hypertrophy and progression of chronic kidney disease.
    Paoletti E
    J Nephrol; 2012; 25(6):847-50. PubMed ID: 22460180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.